ClinicalTrials.gg
RecruitingNCT07063030Updated Mar 10, 2026

A Study of LX107 Gene Therapy in AIPL1-IRD Patients

An Early Phase 1 interventional study of LX107 Injection in Retinal Dystrophy, sponsored by Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine. Recruiting at 1 site in China. Open to participants aged 4 Years and older. Per ClinicalTrials.gov, last updated 2026-03-10.

Sponsored by Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Early Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
13
Allocation
Not applicable
Ages
4 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Retinal Dystrophies with a site in China — 6 open to participants now, 9 under way, 1 of them phase 3. Retinal Dystrophies · China.

Started
2025
with 2 others
Phase 1
4 of 10
3 open now
Registered
9th of 10
by date
Lead sponsor
2 of 10
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Among the 10 studies in Retinal Dystrophies with a site in China, this one is one of 3 that started in 2025, is one of 4 in phase 1, and was the 9th registered.

Retinal Dystrophies

60 studies on the registry are indexed under Retinal Dystrophies; 20 are open to participants now.

Browse Retinal Dystrophies studies →

Open to participants now

6 of the 10 studies in Retinal Dystrophies with a site in China are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 17 Retinal Dystrophies studies recruiting now, 11 (65%) set no upper age limit and 3 (18%) stop at 75 or younger; 6 take children under 18; 5 take healthy volunteers.

This study: 4 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Retinal Dystrophies with a site in China, or all of them as a file.
02

Study summary

Administering subretinal injection of LX107 injection (a gene therapy drug) to patients with retinal dystrophy caused by AIPL1 gene mutation to evaluate its efficacy and safety.

03

Conditions studied

  • Retinal Dystrophy

Browse trials for

04

Who can participate

Ages eligible
4 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  1. The subject and/or their guardian signs a written form and is willing to comply with the long-term follow-up protocol and supporting protocols.
  2. Adult or pediatric patients (aged ≥ 4 years) diagnosed with AIPL1-IRD.
  3. Definitive molecular diagnosis of biallelic AIPL1 gene mutations confirmed by next-generation sequencing combined with Sanger validation.
  4. The study eye has a best-corrected visual acuity of no more than 58 letters (approximately equivalent to decimal visual acuity ≤ 0.3) using the ETDRS visual acuity chart at baseline.

Note: Only one eye will be designated as the "study eye" (i.e., the eye to receive treatment) at the investigator's discretion.

Exclusion Criteria:For any eye with the following conditions:

  1. A history of ocular diseases that, in the investigator's judgment, may hinder the planned treatment or interfere with the interpretation of study endpoints (e.g., glaucoma, diabetic retinopathy, retinal vein occlusion, retinal detachment, posterior or panuveitis, etc.).
  2. Any eye with a history of gene therapy for IRD or other hereditary neuro-ophthalmic diseases (including but not limited to other viral vector-based gene therapies, mRNA therapies, etc.).
  3. A lack of sufficient viable retinal cells as determined by non-invasive methods such as OCT or ophthalmoscopy.
  4. Any active intraocular or periocular infection in the study eye (e.g., infectious conjunctivitis, keratitis, scleritis, endophthalmitis, infectious blepharitis, uveitis).
  5. A history of intraocular surgery (e.g., vitrectomy, cataract surgery, trabeculectomy, or other filtering surgery) in the 6 months prior to the screening visit.

    For any systemic conditions:

  6. Uncontrolled hypertension, defined as systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 100 mmHg. If the initial measurement exceeds the above limits, it may be repeated on the same day or another day during the screening period; if the subject is taking oral antihypertensive drugs, they must have been on a stable dose of the same drug for at least 30 days prior to screening.
  7. Diabetic patients meeting any of the following criteria: ① known to have macrovascular complications; ② baseline > 7.5%; ③ receiving treatment with two or more oral hypoglycemic agents, insulin, or GLP-1 receptor agonists.
  8. A history of any other diseases, metabolic disorders, physical examination findings, or clinical laboratory abnormalities that, in the investigator's judgment, may contraindicate the use of the study drug, interfere with the interpretation of study results, or place the subject at high risk of treatment complications, including but not limited to: AIDS, syphilis, acute/chronic active or C, coagulation disorders, a history of treated or untreated within the past 5 years (except for localized basal cell carcinoma of the skin or in situ cervical cancer), etc.
  9. Any of the following laboratory abnormalities: ① count \< 100 × 10⁹/L, (Hb) \< 10 g/dL (males) or \< 9 g/dL (females); ② (AST) or alanine aminotransferase (ALT) > 3 × ; ③ serum creatinine or urea > 1.5 × ULN.
  10. Administration of any other drug (except vitamins and minerals) within 3 months prior to screening, or an attempt to participate in another clinical trial during the study period.
  11. Other circumstances deemed unsuitable for enrollment by the investigator.
  12. Unwillingness to use effective methods during the study; pregnant or lactating women, or women planning to become pregnant or lactate during the study period.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
13 participants (estimated)

Study arms

  • Experimental
    Intervention

    Experimental: LX107 Injection Arm Description: * Low dose group: subretinal injection of LX107 -3×10⁹ VG/eye * Medium dose group: subretinal injection of LX107- 1×10¹⁰ VG/eye * High dose group: subretinal injection of LX107 -3×10¹⁰ VG/eye

    Genetic: LX107 Injection

Interventions

  • GeneticLX107 Injection

    Subjects will receive subretinal injection of LX107 on Day 0.

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]

    Incidence of ocular and non-ocular adverse events (AEs) and serious adverse events (SAEs) following LX107 subretinal injection

    Time frame: 6 Months

Secondary outcomes

  1. Changes in Functional Magnetic Resonance Imaging (fMRI) Results

    Time frame: 6 months、12 months

  2. Mean Change from Baseline in Multi-luminance Mobility Test (MLMT)

    Assess the subject's mobility ability under different light intensities using MLMT, and compare the mean changes from baseline at 180 and 365 days after treatment to reflect improvements in visual function.

    Time frame: 6 months、12 months

  3. Mean Change from Baseline in Full-Field Sensitivity Threshold (FST)

    Measure the subject's light perception ability using FST, and compare the mean changes from baseline at 180 and 365 days after treatment to evaluate improvements in visual sensitivity.

    Time frame: 6 months、12 months

  4. Mean Change from Baseline in Visual Acuity (VA)

    Measure VA using ETDRS and BRVT charts, with LogMAR score as the indicator, and compare the mean changes from baseline at 180 and 365 days after treatment to assess visual acuity improvement.

    Time frame: 6 months、12 months

  5. Mean Change from Baseline in Visual Fields

    Use Goldmann perimeter (dynamic visual field) and Humphrey perimeter (static visual field) to compare the mean changes from baseline at 180 and 365 days after treatment, evaluating improvements in visual field range and sensitivity.

    Time frame: 6 months、12 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2025 (actual). Primary completion is estimated for Dec 2026, 17 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 3, 2025
First posted
Jul 14, 2025
StartActual
Jul 15, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2030
Last update
Mar 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07063030
Collaborators
Innostellar Biotherapeutics Co.,Ltd
Responsible party
Xiaodong Sun (Director, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine) — Principal investigator
First posted
Jul 14, 2025
Start date
Jul 15, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2030 (estimated)
Last update
Mar 10, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion